Jeil Pharmaceutical

A P-CAB acid suppressant developed by Onconic Therapeutics, indicated for erosive gastroesophageal reflux disease and gastric ulcer; further Phase 3 studies, including non-erosive reflux disease and H. pylori eradication, are under way.

Onconic Therapeutics' anticancer candidate that inhibits both PARP and tankyrase; Phase 2 trials are running in four indications: pancreatic, ovarian, endometrial and gastric cancer.

In-house candidate the company presents as a next-generation diabetes treatment; together with the anticancer candidate JP9441 it is the focus of global business development, including out-licensing.

Plant in Baekam-myeon, Cheoin-gu, Yongin, Gyeonggi-do, producing tablets, capsules and other solid dosage forms, including Jaqbo; a 4,461 m2 solid-dose expansion on the third and fourth floors raises capacity by about 71%.

Expanded the Baekam plant's solid-dose facilities with a total investment of KRW 24.9 billion; equipment qualification runs through December 2026, with product validation and licence changes planned for the first quarter of 2027.

China partner Livzon Pharmaceutical Group dosed the first patient in a Phase 3 trial of an injectable Jaqbo formulation for peptic ulcer bleeding, earning Onconic Therapeutics a USD 1 million milestone; the oral form is under regulatory review in China for reflux disease.

Selected by the Korea Health Industry Development Institute for its second 2026 global expansion support programme for pharma and biotech (K-VIP); it will present JP-2266 and JP9441 at overseas partnering events such as BIO-Europe 2026.